menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

From Pathophysiology to Therapeutic Progress: TYK2's Significance in Plaque Psoriasis

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Our understanding of TYK2’s role in the pathophysiology of psoriasis has recently evolved, leading to new treatment options like deucravacitinib. Deucravacitinib is the first approved TYK2 inhibitor approved for moderate to severe plaque psoriasis. Learn more about this treatment option and the role of TYK2 with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Our understanding of TYK2’s role in the pathophysiology of psoriasis has recently evolved, leading to new treatment options like deucravacitinib. Deucravacitinib is the first approved TYK2 inhibitor approved for moderate to severe plaque psoriasis. Learn more about this treatment option and the role of TYK2 with Dr. Raj Chovatiya and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Uniondale, New York.

Facebook Comments

Schedule25 Jun 2024